What's in Evopoint Biosciences Inc.'s pipeline?

Evopoint Biosciences Inc. has 11 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 8 in Phase 1.

Which companies overlap with Evopoint Biosciences Inc.'s portfolio?

Top competitors by shared drug class: Celgene, Chengdu Zenitar Biomedical Technology Co., Ltd, Jiangsu HengRui Medicine Co., Ltd., Joseph L. Kuti, PharmD, Medical University of Vienna.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/evopoint-biosciences-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Evopoint Biosciences Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evopoint Biosciences Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 1 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Imipenem/Cilastatin/Relebactam	Imipenem/Cilastatin/Relebactam	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; serine beta-lactamases	Infectious Disease
XNW5004 placebo; Chidamide	XNW5004 placebo; Chidamide	phase 3	Histone deacetylase inhibitor	Histone deacetylases	Oncology

Therapeutic area mix

Infectious Disease · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Celgene · 1 shared drug class
Chengdu Zenitar Biomedical Technology Co., Ltd · 1 shared drug class
Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
Joseph L. Kuti, PharmD · 1 shared drug class
Medical University of Vienna · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
NCIC Clinical Trials Group · 1 shared drug class
PharmaMar · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Evopoint Biosciences Inc.:

Cite this brief

Drug Landscape (2026). Evopoint Biosciences Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/evopoint-biosciences-inc. Accessed 2026-05-17.